Use of ceftolozane-tazobactam in a cystic fibrosis patient with multidrug-resistant pseudomonas infection and renal insufficiency

Respiratory Medicine Case Reports

Volumn 23, Issue , 2018, Pages 8-9

  Stokem, Katie ^a   Zuckerman, Jonathan B ^a   Nicolau, David P ^b   Wungwattana, Minkey ^a   Sears, Edmund H ^a  

^a MAINE MEDICAL CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Ceftolozane; Cystic fibrosis; Renal insufficiency; Tazobactam

Indexed keywords

C REACTIVE PROTEIN; CEFTOLOZANE PLUS TAZOBACTAM; CIPROFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ARTICLE; CASE REPORT; CLINICAL ARTICLE; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DYSPNEA; FATIGUE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; KIDNEY FAILURE; MAXIMUM PLASMA CONCENTRATION; MINIMUM CONCENTRATION; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; SIX MINUTE WALK TEST; VOLUME OF DISTRIBUTION AT STEADY-STATE;

EID: 85033213540     PISSN: None     EISSN: 22130071     Source Type: Journal    
DOI: 10.1016/j.rmcr.2017.10.012     Document Type: Article

References (11)

1. Registry, C.F.F.P., 2015 Patient Registry Annual Data Report., 2015.
2. Murano, K., et al. Structural requirements for the stability of novel cephalosporins to AmpC beta-lactamase based on 3D-structure. Bioorg. Med. Chem. 16:5 (2008), 2261–2275.
3. Sutherland, C.A., Nicolau, D.P., Susceptibility profile of ceftolozane/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals. Clin. Ther. 37:7 (2015), 1564–1571.
4. Kuti, J.L., et al. Microbiological activity of ceftolozane/tazobactam, ceftazidime, meropenem, and piperacillin/tazobactam against Pseudomonas aeruginosa isolated from children with cystic fibrosis. Diagn. Microbiol. Infect. Dis. 83:1 (2015), 53–55.
5. Kraynack, N.C., McBride, J.T., Improving care at cystic fibrosis centers through quality improvement. Semin. Respir. Crit. Care Med. 30:5 (2009), 547–558.
6. Sutherland, C.A., Nicolau, D.P., Development of an HPLC method for the determination of ceftolozane/tazobactam in biological and aqueous matrixes. J. Chromatogr. Sci. 54:6 (2016), 1037–1040.
7. Vickery, S.B., McClain, D., Wargo, K.A., Successful use of ceftolozane-tazobactam to treat a pulmonary exacerbation of cystic fibrosis caused by multidrug-resistant Pseudomonas aeruginosa. Pharmacotherapy 36:10 (2016), e154–e159.
8. Monogue, M.L., et al. Population pharmacokinetics and safety of ceftolozane-tazobactam in adult cystic fibrosis patients admitted with acute pulmonary exacerbation. Antimicrob. Agents Chemother. 60:11 (2016), 6578–6584.
9. Miller, B., et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob. Agents Chemother. 56:6 (2012), 3086–3091.
10. Chandorkar, G., et al. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J. Clin. Pharmacol. 55:2 (2014), 230–239.
11. Chandorkar, G., et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J. Antimicrob. Chemother. 67:10 (2012), 2463–2469.